543 related articles for article (PubMed ID: 36232374)
1. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
Vicente ATS; Salvador JAR
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
3. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
4. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.
Li H; Cai X; Yang X; Zhang X
Eur J Med Chem; 2024 Jun; 272():116506. PubMed ID: 38761584
[TBL] [Abstract][Full Text] [Related]
5. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression.
Chen S; Li X; Li Y; Yuan X; Geng C; Gao S; Li J; Ma B; Wang Z; Lu W; Hu HG
Theranostics; 2022; 12(15):6665-6681. PubMed ID: 36185610
[No Abstract] [Full Text] [Related]
6. PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.
Han X; Wei W; Sun Y
Acta Mater Med; 2022; 1(2):244-259. PubMed ID: 35734447
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
8. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
10. Development of selective small molecule MDM2 degraders based on nutlin.
Wang B; Wu S; Liu J; Yang K; Xie H; Tang W
Eur J Med Chem; 2019 Aug; 176():476-491. PubMed ID: 31128449
[TBL] [Abstract][Full Text] [Related]
11. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
12. PROTACs: Promising approach for anticancer therapy.
Kaur SD; Bedi N; Kumar D; Kapoor DN
Cancer Lett; 2023 Mar; 556():216065. PubMed ID: 36642326
[TBL] [Abstract][Full Text] [Related]
13. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors.
Si R; Hai P; Zheng Y; Liu N; Wang J; Zhang Q; Li Y; Pan X; Zhang J
Bioorg Med Chem Lett; 2023 May; 87():129275. PubMed ID: 37030566
[TBL] [Abstract][Full Text] [Related]
15. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
17. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
[TBL] [Abstract][Full Text] [Related]
18. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
19. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Studies of PROTACs in Hematological Malignancies.
Fuchs O; Bokorova R
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]